Clinical trial
A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura…
NCT04435366 · IVERIC bio, Inc., Industry · Completed
Key facts
| NCT number | NCT04435366 |
|---|---|
| Title | A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor) |
| Official title | A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration |
| Lead sponsor | IVERIC bio, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Geographic Atrophy, Macular Degeneration |
| Intervention type | Drug |
| Interventions | Avacincaptad Pegol, Sham |
| Enrollment | 448 |
| Start date | Jun 22, 2020 |
| Primary completion | Jul 25, 2022 |
| Completion | Aug 22, 2023 |
| First posted | Jun 17, 2020 |
| Last update posted | Oct 21, 2025 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Croatia, Czechia, Estonia, France, Germany and 8 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: